Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × INDUSTRY × vandetanib × Clear all

Phase

Status

Completed 34 Terminated 5 Withdrawn 1 Active not recruiting 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Medullary 1

Interventions

pembrolizumab 169 Carboplatin 116 Paclitaxel 92 Cisplatin 86 Gemcitabine 77 durvalumab 69 Nivolumab 64 Pemetrexed 63 Cyclophosphamide 56 Docetaxel 45 Capecitabine 44 atezolizumab 43 Dexamethasone 43 Oxaliplatin 42 130-nm albumin-bound paclitaxel 42 Bevacizumab 41 Lenalidomide 40 Fluorouracil 38 Rituximab 37 Prednisone 32 Fulvestrant 32 osimertinib 30 fludarabine 30 Leucovorin 28 venetoclax 27 olaparib 26 Trastuzumab 26 Doxorubicin 26 Azacitidine 24 Etoposide 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04211337 2025-04-20

LIBRETTO-531

Eli Lilly and Company

Phase 3 Active not recruiting

291 enrolled 16 charts 1 FDA

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡